Evidence map›Paper›PMID 33141922›Full record

ArticleClinical pharmacology and therapeutics2021

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters.

Brahim Achour, Zubida M Al-Majdoub, Agnieszka Grybos-Gajniak, Kristi Lea, Peter Kilford, Mian Zhang, David Knight, Jill Barber, Jeoffrey Schageman, Amin Rostami-Hodjegan

Open access · hybridAbstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Brahim AchourCentre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
Zubida M Al-MajdoubCentre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
Agnieszka Grybos-GajniakIllumina, Cambridge, UK.
Kristi LeaThermo Fisher Scientific, Austin, Texas, USA.
Peter KilfordSimcyp Division, Certara Ltd., Sheffield, UK.
Mian ZhangSimcyp Division, Certara Ltd., Sheffield, UK.
David KnightBiological Mass Spectrometry Core Facility, University of Manchester, Manchester, UK.
Jill BarberCentre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
Jeoffrey SchagemanThermo Fisher Scientific, Austin, Texas, USA.
Amin Rostami-HodjeganCentre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
University of Manchester · GBSimcyp (United Kingdom) · GBThermo Fisher Scientific (United States) · USIllumina (United Kingdom) · GBManchester Academic Health Science Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variability in individual capacity for hepatic elimination of therapeutic drugs is well recognized and is associated with variable expression and activity of liver enzymes and transporters. Although genotyping offers some degree of stratification, there is often large variability within the same genotype. Direct measurement of protein expression is impractical due to limited access to tissue biopsies. Hence, determination of variability in hepatic drug metabolism and disposition using liquid biopsy (blood samples) is an attractive proposition during drug development and in clinical practice. This study used a multi-"omic" strategy to establish a liquid biopsy technology intended to assess hepatic capacity for metabolism and disposition in individual patients. Plasma exosomal analysis (n = 29) revealed expression of 533 pharmacologically relevant genes at the RNA level, with 147 genes showing evidence of expression at the protein level in matching liver tissue. Correction of exosomal RNA expression using a novel shedding factor improved correlation against liver protein expression for 97 liver-enriched genes. Strong correlation was demonstrated for 12 key drug-metabolizing enzymes and 4 drug transporters. The developed test allowed reliable patient stratification, and in silico trials demonstrated utility in adjusting drug dose to achieve similar drug exposure between patients with variable hepatic elimination. Accordingly, this approach can be applied in characterization of volunteers prior to enrollment in clinical trials and for patient stratification in clinical practice to achieve more precise individual dosing.

Indexed as

AdultAgedAged, 80 and overBiological TransportCytochrome P-450 Enzyme SystemExosomesFemaleHumansInactivation, MetabolicLiquid BiopsyLiverMaleMembrane Transport ProteinsMetabolic Clearance RateMiddle AgedYoung AdultCytochrome P-450 Enzyme SystemMembrane Transport Proteins

Identifiers

PMID33141922
PMCPMC7839483
OpenAlexW3097132215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.